OneDigital Investment Advisors LLC decreased its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 11.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,417 shares of the conglomerate’s stock after selling 1,544 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Danaher were worth $3,174,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of DHR. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher in the 2nd quarter worth $25,000. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Danaher during the 2nd quarter worth about $51,000. Financial Connections Group Inc. acquired a new stake in Danaher during the 2nd quarter worth approximately $51,000. Finally, Western Pacific Wealth Management LP purchased a new position in Danaher in the first quarter valued at approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Insider Buying and Selling
In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 11.10% of the company’s stock.
Danaher Stock Performance
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.02 EPS. The company’s revenue was up 3.1% on a year-over-year basis. On average, equities research analysts expect that Danaher Co. will post 7.51 earnings per share for the current year.
Danaher Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.47%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 20.61%.
Wall Street Analysts Forecast Growth
DHR has been the subject of several research reports. KeyCorp boosted their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Barclays lowered their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Leerink Partners upped their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Bank of America increased their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, Stephens restated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $287.16.
Get Our Latest Research Report on DHR
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- Which Wall Street Analysts are the Most Accurate?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Differences Between Momentum Investing and Long Term Investing
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Time to Load Up on Home Builders?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.